tradingkey.logo

EyePoint Pharmaceuticals Inc

EYPT
View Detailed Chart

10.040USD

+0.330+3.40%
Market hours ETQuotes delayed by 15 min
690.87MMarket Cap
LossP/E TTM

EyePoint Pharmaceuticals Inc

10.040

+0.330+3.40%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.40%

5 Days

-4.20%

1 Month

+3.29%

6 Months

+40.03%

Year to Date

+34.77%

1 Year

+14.74%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 14 analysts
BUY
Current Rating
32.167
Target Price
231.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

173
Total
5
Median
8
Average
Company name
Ratings
Analysts
EyePoint Pharmaceuticals Inc
EYPT
14
Biogen Inc
BIIB
37
Alnylam Pharmaceuticals Inc
ALNY
34
Vertex Pharmaceuticals Inc
VRTX
34
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(4)
Neutral(2)
Buy(4)
Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.338
Neutral
RSI(14)
47.870
Neutral
STOCH(KDJ)(9,3,3)
8.897
Oversold
ATR(14)
0.524
Low Volatility
CCI(14)
-127.762
Sell
Williams %R
91.425
Oversold
TRIX(12,20)
0.347
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
9.850
Buy
MA10
10.191
Sell
MA20
10.226
Sell
MA50
9.126
Buy
MA100
7.568
Buy
MA200
8.006
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Ticker SymbolEYPT
CompanyEyePoint Pharmaceuticals Inc
CEODr. Jay S. Duker, M.D.
Websitehttps://eyepointpharma.com/
KeyAI